Survival analysis showed that the survival time of ovarian cancer patients with the TRIB3 mutation was significantly shorter as compared to that of patients without the mutation, indicating that the TRIB3 mutation can predict the survival and prognosis of patients with ovarian cancer. This evidence concerns the gene TRIB3 and ovarian carcinoma.